SCHEMBL4054692

SCHEMBL4054692

Fc1ccccc1C=Cc1nc2ccc(-c3ccccc3)cc2o1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
METAP2 P50579 1/20 0.44
NFE2L2 Q16236 6/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
ALDH1A1 P00352 2/20 0.43
HPGD P15428 2/20 0.43
NPSR1 Q6W5P4 1/20 0.43
NPC1 O15118 4/20 0.40
RAB9A P51151 4/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
PKM P14618 1/20 0.40
NFKB1 P19838 1/20 0.40
NFKB2 Q00653 1/20 0.40
RELA Q04206 1/20 0.40
KDM4E B2RXH2 1/20 0.40
MAPT P10636 1/20 0.40
HTT P42858 1/20 0.40
CHEK1 O14757 1/20 0.39
CDK1 P06493 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4054688 1.00 METAP2 (0.44) METAP2NFE2L2SMN1; SMN2MEN1KMT2A
SCHEMBL4054255 0.91 SMN1; SMN2 (0.53) METAP2NFE2L2SMN1; SMN2MEN1KMT2A
SCHEMBL4054261 0.91 SMN1; SMN2 (0.53) METAP2NFE2L2SMN1; SMN2MEN1KMT2A
SCHEMBL4062306 0.90 NFE2L2 (0.48) NFE2L2SMN1; SMN2MEN1KMT2AALDH1A1
SCHEMBL4062300 0.90 NFE2L2 (0.48) NFE2L2SMN1; SMN2MEN1KMT2AALDH1A1
SCHEMBL4062200 0.84 PIK3R1 (0.44) METAP2NFE2L2SMN1; SMN2MEN1KMT2A
SCHEMBL4062204 0.84 PIK3R1 (0.44) METAP2NFE2L2SMN1; SMN2MEN1KMT2A
SCHEMBL4051814 0.83 UTRN (0.53) SMN1; SMN2MEN1KMT2AALDH1A1HPGD
SCHEMBL4051820 0.83 UTRN (0.53) SMN1; SMN2MEN1KMT2AALDH1A1HPGD
SCHEMBL4060235 0.82 NFE2L2 (0.44) METAP2NFE2L2SMN1; SMN2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7622479-B2 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-24 US disclosed
US-20050101647-A1 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-05-12 US disclosed
EP-1460067-A1 BICYCLIC DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE Takeda Chemical Industries, Ltd. (JP) 2004-09-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050101647-A1 Bicyclic derivative, its production and use ABL1, SRC, PTK2B METAP2 4556/4885NFE2L2 996/4885SMN1; SMN2 4289/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.